Back to search results

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Low-Grade Serous Ovarian Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Emory Winship Cancer Institute, Atlanta, Georgia, United States

    Contact: Study coordinator (Beryl Manning-Geist, MD) · 404-778-3401

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

    Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

    Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

    Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653

  • Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities), Commack, New York, United States

    Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), East White Plains, New York, United States

    Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653
    Contact: Study coordinator (Chrisann Kyi, MD) · 646-888-4221
    Contact: Principal Investigator (Rachel Grisham, MD)

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States

    Contact: Study coordinator (Rachel Grisham, MD) · 646-888-4653
Study leads

  • Rachel Grisham, MD

    Principal Investigator

    Memorial Sloan Kettering Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)